NCT05410821View on ClinicalTrials.gov

Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 15, 2022

Primary Completion Date

June 15, 2024

Study Completion Date

March 27, 2025

Conditions
Refractory Thyroid Gland CarcinomaRefractory Thyroid Gland Papillary CarcinomaRefractory Thyroid Gland Follicular CarcinomaRefractory Thyroid Gland Hurthle Cell Carcinoma
Interventions
DRUG

177Lu-DOTA-EB-FAPI 1 radionuclide therapy

radionuclide therapy using 177Lu-DOTA-EB-FAPI 60 mCi (2.22 GBq) will be performed 6-weekly. A maximum of 2 cycles will be administered.

DRUG

177Lu-DOTA-EB-FAPI 2 radionuclide therapy

radionuclide therapy using 177Lu-DOTA-EB-FAPI 90 mCi (3.33 GBq) will be performed 6-weekly. A maximum of 2 cycles will be administered.

DRUG

177Lu-DOTA-EB-FAPI 3 radionuclide therapy

radionuclide therapy using 177Lu-DOTA-EB-FAPI 135 mCi (4.99 GBq) will be performed 6-weekly. A maximum of 2 cycles will be administered.

Trial Locations (1)

361000

The First Affiliated Hospital of Xiamen University, Xiamen

All Listed Sponsors
lead

The First Affiliated Hospital of Xiamen University

OTHER